For instance, survival rates vary significantly among different cancer types in CPG mutation carriers, with BRCA2-mutation-positive ovarian cancer patients experiencing significantly better outcomes and BRCA2-mutation-positive prostate cancer patients facing a less favorable prognosis. The gene discussed is BRCA2; the disease is prostate carcinoma.